PET/CT of cranial arteries for a sensitive diagnosis of giant cell arteritis

Rheumatology (Oxford). 2023 Apr 3;62(4):1568-1575. doi: 10.1093/rheumatology/keac430.

Abstract

Objectives: To investigate the performance of cranial PET/CT for the diagnosis of GCA.

Methods: All patients with a suspected diagnosis of GCA were prospectively enrolled in this study and had a digital PET/CT with evaluation of cranial arteries if they had not started glucocorticoids >72 h previously. The diagnosis of GCA was retained after at least 6 months of follow-up if no other diagnosis was considered by the clinician and the patient went into remission after at least 6 consecutive months of treatment. Cranial PET/CT was considered positive if at least one arterial segment showed hypermetabolism similar to or greater than liver uptake.

Results: For cranial PET/CT, sensitivity (Se), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV) were 73.3%, 97.2%, 91.7% and 89.7%, respectively. For extracranial PET/CT, diagnostic performance was lower (Se = 66.7%, Sp = 80.6%, PPV = 58.8%, NPV = 85.3%). The combination of cranial and extracranial PET/CT improved overall sensitivity (Se = 80%) and NPV (NPV = 90.3%) while decreasing overall specificity (Sp = 77.8%) and PPV (PPV = 60%).

Conclusion: Cranial PET/CT can be easily combined with extracranial PET/CT with a limited increase in examination time. Combined cranial and extracranial PET/CT showed very high diagnostic accuracy for the diagnosis of GCA.

Trial registration: ClinicalTrials.gov, https://clinicaltrials.gov, NCT05246540.

Keywords: GCA; PET CT; diagnosis.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arteries
  • Fluorodeoxyglucose F18
  • Giant Cell Arteritis* / diagnostic imaging
  • Humans
  • Positron Emission Tomography Computed Tomography
  • Predictive Value of Tests
  • Temporal Arteries

Substances

  • Fluorodeoxyglucose F18

Associated data

  • ClinicalTrials.gov/NCT05246540